Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

SpringWorks' Investigational Cancer Treatment Is Standard Care, Analyst Unfazed By FDA Update

Published 24/08/2023, 19:35
© Reuters.  SpringWorks' Investigational Cancer Treatment Is Standard Care, Analyst Unfazed By FDA Update
SWTX
-

Benzinga - by Vandana Singh, Benzinga Editor.

In March, the FDA issued SpringWorks Therapeutics Inc (NASDAQ: SWTX) with a Form 483 letter due to a failure to ensure that the analysis of an exploratory endpoint in the Phase 3 DeFi trial, which evaluated nirogacestat for the treatment of desmoid tumor (DT) patients that have experienced progressive disease.

Desmoid tumors are noncancerous growths that occur in the connective tissue. Desmoid tumors most often occur in the abdomen, arms, and legs.

In June, SpringWorks Therapeutics announced that the FDA updated the Prescription Drug User Fee Act action date for the New Drug Application for nirogacestat from the previous date of August 27, 2023, by three months.

HC Wainwright notes that new tumors were included in calculating the sum of target tumors for seven patients, which was not under the statistical analysis plan (SAP).

However, there was no change to nirogacestat's efficacy profile after SpringWorks corrected the analysis.

The analysts Robert Burns and Raghuram Selvaraju note that the FDA has completed all required inspections.

Accordingly, given the strength of the DeFi trial results, the analysts continue to view nirogacestat as the eventual standard-of-care regimen for treating DTs and write that it should ultimately receive FDA approval, including pain reduction in the label.

The analyst reiterates the Buy rating for the stock with a price target of $66, noting that the FDA inspection report does not alter the analyst's conviction regarding nirogacestat's probability of approval.

Price Action: SWTX shares are down 2.42% at $27.78 on the last check Thursday.

Latest Ratings for SWTX

DateFirmActionFromTo
Sep 2021JP MorganMaintainsOverweight
Aug 2021HC Wainwright & Co.MaintainsBuy
Jul 2021HC Wainwright & Co.MaintainsBuy
View More Analyst Ratings for SWTX

View the Latest Analyst Ratings

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.